


Summer | Autumn 2016





Biobased World

The premier trade show for all biobased industries

Showcase your expertise in bioeconomy at the trade show that takes the bioeconomy from "let's talk about it" to "let's do it"



www.biobasedworld.de

15-16 February 2017 Cologne · Germany

industrial biotechnology · algae · biomass · biorefinieries · biopolymers · bioenergy · biofuels · biobased chemicals · biobased lubricants · biobased surfactants · biobased materials

Need a biotech update?

EVENT GUIDE The EuroBioFairs Compass shows you which conference, trade fair or partnering show to mark on your event calender.

From scientific congresses to partnering, from trade fairs to technology offerings – this coming autumn will cover a series of highlights that could have an impact on your business. However, the growing number of events demand careful choices. This edition of the Euro BIOFAIRS COMPASS presents the must-attend events in the months to come. Whether you're looking for a licensing partner, need funding or just want to find out more about the latest R&D developments and services, you'll find everything you need to know about what each event provides.

Based on advanced partnering and networking tools, **Nordic Life Science Days** (see p. 44) showcases the best the Nordic region has to offer. The mix of conference, partnering and exhibition is hosted in Stockholm (14–15 September).

Spotlight on business

Starting on 26 September, a whole week will be dedicated to communicating the benefits of biotech to the public. The **European Biotech Week** (see p. 46) is organised by EuropaBio, the European Association for Bioindustries, and features more than 200 events across Europe.

Pitching and biotech-pharma partnering will be at the centre of BIO Deutschland's **European Business Development Conference** (see p. 48) in Frankfurt. The event will illuminate new treatment paradigms such as cell therapies and immuno-oncology (27–28 September).

The fifth largest partnering event in Europe, an investment and employment forum, a trade fair, and scientific conferences all in one international show – this is what the 8th **Biospain** in Bilbao (28–29 September, see p. 50) will be about.

Interested in the latest trends in the pharmaceutical industry? Don't miss the

CPhI Worldwide. This year the branch will meet in Barcelona (4–6 October, see p. 52). Last time the show attracted more than 36,000 life sciences professionals and 2,500 companies showcased.

Enterprises aiming to expand in the Far East are well-advised to attend Asia's largest biotech event, **BioJapan 2016** (12–14 October, see p. 54), which for the first time is being carried out in conjunction with Regenerative Medicine JAPAN.

The biotech industry's largest partnering event, **EBD's BioEurope** (7–9 November) in Cologne, will provide the perfect meeting point for biotechs, investors and pharma executives (see p. 56).

The biosimilars pathway

For the fourth year running, **PharmaLab** (see p. 58) calls upon the latest regulatory and scientific developments in all laboratory areas of the pharmaceutical industry (8–9 November). The event, to be held in Neuss, is accompanied by an exhibition, in which suppliers of lab equipment, and contract laboratories present their offerings.

A decade after the EMA introduced a regulatory pathway for biosimilars in the EU, DIA is arranging its 4th annual EU conference on this evolving regulatory topic to keep all relevant stakeholders up to date. The **European Biosimilars Conference** (see p. 60) will be hosted in Brussels (9–10 November).

More than 1,200 delegates and 800 companies are expected to attend the **BioFIT 2016** (see p. 62) in Lille, a key date for everyone who is interested in partnering, technology transfer and early licencing (30 November–1 December).


Just turn the page to learn everything you need to know about Europe's mustattend events in the biotech industry.

NEW: European Biotechnology Guide Vol. 6

Out now! The European Biotechnology Science & Industry Guide 2016 provides a wealth of information on companies, research institutions, tech parks and providers acting in the life sciences and biotech industry. In addition to the detailed portraits on about 220 pages, this brand new edition contains a summary of BIOCOM's latest report "Analysis of European biotech companies on the stock market: US vs Europe". Discover the many success stories and the current trends in the biotech industry today!



European Biotechnology Science & Industry Guide Vol. 6 €19.80 ISBN 978-3-928383-58-5 Tel. +49 (0)30/264921-48 Fax +49 (0)30/264921-11 service@biocom.eu www.biocom.eu





14-15 September, 2016 Waterfront Conference Center Stockholm, Sweden

Time for partnering

NORDIC LIFE SCIENCE DAYS Founded in 2012, the Nordic Life Science Days is the largest Nordic partnering conference for the global life science industry. The event brings together the best talents in life science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends.

The Nordic region is proud to host some of the world's most innovative biotech, medtech and pharma companies. It also has the twelfth strongest economy, making it the perfect place to invest. Set in the idyllic city of Stockholm, the conference offers conference sessions, panel discussions, company presentations, exhibition, face-to-face meetings and unique receptions, providing so many opportunities to net-

work with peers, potential partners and investors.

Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.

Partnering at NLSDays is powered by the leading web-based partnering system. With partnering ONE you can facilitate: search for partners, customers or clients, request meetings with selected companies, accept or decline meeting requests from others and get your personal meetings schedule prior to the conference.

Learn about the latest trends and success stories in therapeutic areasfocused sessions on R&D, Business Development and Investment and connect to key executives speaking at NLS-Days. The programme features high executive level keynote speakers and panelists who openly share their insights and opinions on many important life science issues.

Welcome

Greeting Bionordic is a global event management company, organising and producing conferences and corporate events. Based in Stockholm, the



company supports a large range of international clients including public and private agencies, non-governmental organisations, regional and multinational corporations.

We are part of the new life science ecosystem, being innovative, creating content and value for our customers. We conceive, produce and deliver unique events and substantial partnering and networking opportunities.

Based on cutting edge and technology solutions, we offer our clients a full in-house specialist event management service supported by a passionate team of experts focused on creating amazing events. We are proud to be the official producer of the Nordic Life Science Days, a SwedenBIO event.

In 2016, we look forward to welcoming Oslo Cancer Cluster as Special Programme Host for our Oncology track.

> QUICK FACTS

2015 Highlights

1,025 participants
630 companies from 30 countries
9,500 meeting requests
1,940 scheduled meetings
540 licensing opportunities

Registration and information

www.nlsdays.com Phone +33 608 804 515 olivier.duchamp@bionordic.com

Olivier Duchamp

Managing Director Nordic Life Science Days Chairman & CEO Bionordic Services

NLSDAYS 2016 Nordic Life Science Days

September 14-15, 2016 Stockholm, Sweden



Special NLSDays' Oncology Program Host

Invest Partner Network • entering into new deals

- new partnering opportunities
- 2 days for meeting the best Nordic Region has to offer



Register at www.nlsdays.com.





26 September-2 October, 2016 Different locations across whole Europe

Tribute to biotech

EUROPEAN BIOTECH WEEK European Biotech Week calls on the biotech community to start planning events and activities for the week starting 26 September to make biotech more accessible, understandable and hopefully exciting.

At EuropaBio, the European Association for Bioindustries, we realise how important it is to foster dialogue and information sharing in the scientifically complex and often misunderstood area of biotechnology.

Our members are committed to developing tools and solutions for some of the world's main challenges, and we have a responsibility to share what we know and to facilitate an open discussion among all stakeholders to accompany these developments.

European Biotech Week was first coined in 2013 to mark the 60- year anniversary of the discovery of DNA's structure. Every year, together with its member National Associations, EuropaBio promotes the week and provides a platform for all biotech supporters to pool their events and raise awareness about the products and the benefits that biotechnology brings to

areas as diverse as healthcare, agriculture, food, energy and industrial processing.

Year upon year, the participation in European Biotech Week has increased with a record 15 countries taking part in the 2015 edition. The 100+ initiatives organised in the areas of science, education, policy, media and finance involved thousands of Europeans. Importantly, numerous events were related to jobs and training, including career fairs and hands-on laboratories for adults, students and children, competitions, open doors in companies, research institutes and museums as well as theatrical shows. At a national level, the initiative was even awarded a medal by the Italian President of the Republic.

EuropaBio strongly encourages all biotech supporters to join forces and participate in whatever way best fits with their mission and resources.

Better together

GREETING From the medicines we use, to the clothes we buy and the detergents we wash them with, few other sectors en-



hance quality of life, knowledge, innovation, productivity and environmental protection like biotechnology. The biotech industry should be proud of its achievements and present its current successes and future plans to end-users. We really hope that European Biotech Week becomes a self-perpetuating week that opens the doors to a better understanding of the world we live in. It is a unique opportunity for those people, organisations and companies who care about biotech to unravel and debate why there's no science like biotech science!

Nathalie Moll

Secretary General, EuropaBio

QUICK FACTS

In 2015

60% of Europe involved 100+ events 19% growth on Twitter

CONTACT

Mélanie Moxhet

m.moxhet@europabio.org www.biotechweek.org

Get involved in European Biotech Week!

If you are familiar with biotechnology, you know the field provides incredibly innovative solutions for the benefit of mankind despite it often being unknown or misunderstood. That is why the biotech community needs you or your organisation to help raise awareness and make biotech more accessible.

Now in its fourth year, European Biotech Week has offered all supporters of biotechnology the opportunity to host events and develop initiatives that contribute to an increased dialogue and understanding of this amazing technology. Potential activities are as varied as the supporters themselves, and the organisers of the Week¹ always encourage new ideas and feedback. For inspiration, flip through the magazines of the past editions on www.biotechweek.org.

There are no fees or hidden costs involved. All organisers can pool their activities on www.biotechweek.org for increased visibility and promotion, and they will later be featured in a widely-distributed post-week magazine. Interested? Please contact Mélanie Moxhet (m.moxhet@europabio.org).

¹EuropaBio – the European Association for Bioindustries – together with its member National Biotech Associations













Part of



biotechweekbiotechweekwww.biotechweek.org



26 Sept > 2 Oct 2016



Bio Deutschland

Biotechnologie-Industrie-Organisation Deutschland e. V.

27-28 September, 2016 Sheraton Offenbach Hotel, Offenbach, Germany

Partnering plus

EUROPEAN BUSINESS DEVELOPMENT CONFERENCE The EBDC, BIO

Deutschland's annual business development event, provides excellent opportunities to further your business contacts.

Around half of all innovative drugs result from national – but especially international – collaborations.

The European Business Development Conference (EBDC) provides a forum for making contacts and discussing topics and trends of relevance to the drug development market. The conference's participants come from a wide range of backgrounds. Decision makers from innovative biotechnology firms can meet business development managers from pharmaceutical companies, finance

professionals, service providers and consultants. This means that you have the opportunity to meet experts from all areas of business development. The event is thus an ideal occasion for making contacts of strategic and operational importance.

The EBDC is a two-day meeting that aims to bring a selected group of business development executives from international pharmaceutical corporations and European biotech companies together with representatives from private

equity and venture capital companies. For EBDC attendees, partnering is an additional benefit for great networking. But it will be not the only format. It is a start, the opportunity to make a first pitch. But you will also have enough time for an on-site follow-up. EBDC partnering is not about spending two days in a partnering box. It is a conference with a wide range of hot topics. It is about open discussions about promises and risks of certain technologies, about the sharing of experiences in certain fields with much more time to go into detail than at a regular masspartnering event.

The conference venue (Sheraton Offenbach Hotel, Berlin Str. 111, 63065 Offenbach) is centrally located just 30 minutes away from Frankfurt Airport with ground transportation and 15 minutes from Frankfurt Central station. This means easy access to a valuable conference and networking experience.

Better together

GREETING Germany is one of the world's leading medical biotech nations. A unique infrastructure offers whole value-added



chains from academic research to marketed products in the most important biotech clusters, the so called bioregions. This year the EBDC will take place in the German State of Hesse, which is one of the heavyweights in the German biotech and pharma industry. It houses about 225 life science companies generating an annual turnover of more than €6bn. I would like to personally encourage you to attend the EBDC, partner our innovative German biotech companies and learn about the benefits of the excellent industry infrastructure.

Dr. Peter HeinrichChairman of the Board
BIO Deutschland

> QUICK FACTS

Programme highlights

- > Trends in Immuno-Oncology
- > Europe's financial landscape
- > Cures for neurologic diseases
- > Cell & gene therapy
- > R&D challenges of orphan meds

Contact & registration

events@biodeutschland.org Phone: +49 (0)30 726 25 130 www.biodeutschland.org/ebdc2016

Biotechnologie-Industrie-Organisation Deutschland e.V.

27 to 28 September 2016 | Frankfurt am Main/Offenbach | Germany

European Business Conference Development Conference



Platinum Sponsors:





Gold Sponsors:







































biospain 2016

28-30 September, 2016 Bilbao Exhibition Centre Bilbao, Spain

Bilbao biotech bash

BIOSPAIN The Spanish Bioindustry Association (ASEBIO) and SPRI (Basque Business Development Agency), part of the Basque Government Department of Economic Development and Competitiveness, have signed an agreement for the city of Bilbao to host the 8th edition of biannually held Biospain.

From the 28th to the 30th of September 2016, the Bilbao Exhibition Centre (BEC) in Greater Bilbao's city of Barakaldo will be the stage for Biospain 2016, a forum for all the actors in the biotechnology sector to share knowledge, ideas and experiences.

Biospain is made up of a commercial fair, a partnering event, an investment forum, an employment forum, conferences on a range of issues (with parallel sessions) and a congress which is organised Committee of Biospain 2016 has selected four scientific societies to organise the scientific congress at the event: the Spanish Society for Immunology, the Spanish Society of Haematology and Haemotherapy, the Spanish Society of Infectious Diseases and Clinical Microbiology and the Spanish Proteomics Society. The Spanish Biotechnology Society will also participate and is organising a parallel session. Francisco Mojica, the first researcher to characterise and coin the term CRISPR technology, has confirmed his attendance.

by scientific societies. The Organising

The Biospain Investment Forum will have the support of the Spanish Venture Capital & Private Equity Association (ASCRI), which aims to attract both national and international investors. Moreover, the third edition of the Training and Employment Forum is being organised in collaboration with FEBiotec, the Spanish Federation of Biotechnologists. The forum will go beyond showcasing training opportunities for the sector by making use of a system of scheduled interviews that will connect employers and job hunters.

Replicating a hit

edition of Biospain will take place in September 2016, and once again in Bilbao. Our experience in Euskadi with Biospain 2012 was exceptional



because of the high attendance, the excellent facilities and the involvement of a local government which is highly committed to R&D. We hope to have similar success for this edition. Biospain is today the 5th largest partnering event in biotechnology in the world, with 3,327 one-to-one meetings in 2014, +320% more meetings than the first time the partneringONE system (EBD Group) was introduced in 2008 and +20% more than 2012.

Following the success of previous editions, Biospain 2014 hosted 200 exhibitors, more than 850 companies and institutions and over 1,850 delegates from 37 countries. 50% of the commercial fair space is already allocated. Some of the most stand-out subject areas include: a patient forum on rare diseases, multiple sclerosis and the increasingly bigger role played by patient organisations; new diagnostics methods; vaccines; Alzheimer's; food and health; public policies for open innovation; nanobiotechnology; big data; new oncology therapies, and bioeconomy. See you in Bilbao!

Jordi MartiPresident ASEBIO

> QUICK FACTS

Registration

www.biospain2016.org /information-registration

Pintxos Networking

On 29 September a tapas tour is taking place in downtown Bilbao. Called pintxos in the Basque Country, these tapas are ususally eaten as a small snack while hanging out with friends, relatives – or Biospain delegates.

biospain 2016

8th International Meeting on Biotechnology September 28-30, 2016 Bilbao, Spain

Bilbao Exhibition Center

www.biospain2016.org

Organized by:











Official sponsors:













4-6 October, 2016 Fira de Barcelona Gran Via Barcelona, Spain

Shaping the industry

CPHI WORLDWIDE Once again the world's most prominent pharma executives will gather for three days of networking, informative conferencing and meetings that will help shape the industry. This year's edition sees 36,000 visitors from more than 153 countries meeting under one roof.

At CPhI Worldwide there will be over 20 dedicated zones covering ingredients, APIs, excipients, contract services, packaging, biopharm, machinery and many more. Running alongside the pharmaceutical ingredients halls are four other sister brands, which help visitors to quickly identify the right halls for their needs.

ICSE is an outsourcing focused area designed to connect the pharmaceutical community with contract providers from clinical trials, CROs, logistics

providers, data management firms and CMOs. InnoPack is where packaging and pharmaceutical industries meet. P-Mec Europe features exhibitors from traditional large-scale capital equipment to companies focused on instrumental analysis, measuring and testing technologies, materials testing, quality control and laboratory. And, this year will see the launch of Finished Dose Formulation (FDF) as a co-located event – a dedicated platform for every aspect of the finished dosage supply chain.

Make sure you also attend the CPhI Pre-Connect Congress, an excellent opportunity to join senior executives and influential speakers in discussing the most recent innovations, trends and market developments. Three separate tracks offer market-led educational modules. Sessions in track one feature 'Contract Services' and 'Drug Delivery and Design'; while sessions in track two contain modules across 'Ingredients, Chemicals and Excipients' and 'Biologics & Biosimilars'. Track three sessions will focus on 'Finished Dosage & Generics' and 'Pharmaceutical Packaging'.

Breaking records

GREETING As CPhI Worldwide makes it first ever visit to Barcelona in 2016, where the entire pharma community will once again gather to learn, exhibit and network



with the leading decision makers and innovators across this industry. As in the past, the event holds a unique position due to hosting the largest number of traditional pharmaceutical buyers, alongside an array of top biopharmaceutical companies.

Last year was an incredible event for CPhI, as we celebrated our 26th anniversary with our largest show to date. This year we are on course for another record-breaking show with an expanded conference platform, increased content sharing and greater networking opportunities across the event's huge range of diverse platforms. Additionally, the show sees the return of the revamped CPhI Pharma Awards that feature more categories than ever before and more than 100 free industry seminars. On behalf of UBM EMEA, I look forward to welcoming you to CPhI Worldwide 2016 and thank all of our partners that make this the best, most informative, and essential pharma event in the global calendar.

> QUICK FACTS

Partnering

A unique matchmaking programme allows attendees to find and connect with particular companies specific to their business needs.

Registering for visitors at

www.cphi.com/europe/visit

Booking for exhibitors at

www.cphi.com/europe/exhibit

Chris Kilbee,

Group Director Pharma, UBM EMEA



Mix with the world of pharma, products, people and solutions

Join the world's leading pharmaceutical event

CPhI Worldwide hosts over 36,000+ visiting pharma professionals, 2,500+ exhibitors from 150+ countries and more than 100 free industry seminars, covering every sector under one roof. Attending CPhI Worldwide is the most cost effective way to establish new business relationships, meet with global partners and stay updated on the latest industry trends.



"Being part of the CPhI family to me is about being part of the very best the industry has to offer. With opportunities to meet suppliers, distributors, logistic specialists and customers all at one time all in one place, CPhI offers us the prospect to exponentially grow our business."

Matthew Rosen

CEO Global Pharmaceuticals Relief, LLC



Co-located with:










4-6 October 2016 · Fira Barcelona - Gran Via · Spain

www.cphi.com/europe Join the conversation @cphiww using #cphiww







12-14 October, 2016 Yokohama, Japan

Partnering in Japan

BIOJAPAN Japan's regular Bio Meeting and Exhibition held since 1986, has grown to become Asia's largest partnering event over the last few years. BioJapan 2016 will take place from 12–14 October, 2016 in Yokohama along with a new event focusing on regenerative medicine.

Each year in October, representatives from Japanese and global pharmaceutical and biotech companies, universities and research institutes gather in Yokohama for BioJapan to exchange information on the latest trends in the industry, to identify new business opportunities and to build strategic relationships. The event continues to grow steadily. This year, over 800 exhibitors and 15,000 visitors are expected to participate in BioJapan and a significant number of them will engage

in partnering meetings. The organisers estimate over 8,000 scheduled meetings. "Regenerative Medicine JAPAN" will be organised concurrently with BioJapan for the first time, co-hosted by the Japan Bioindustry Association and the Forum for Innovative Regenerative Medicine.

Since Professor Shinya Yamanaka received the Nobel Prize for his research on iPS cells in 2012, Japan has been investing heavily in the field of regenerative medicine. A revision of the Pharmaceutical Affairs Law in 2014 introduced the world's fastest approval scheme for such medicines. Many Japanese and foreign companies are pursuing this opportunity in the world's 2nd largest medical market. BioJapan and Regenerative Medicine JAPAN will feature exhibition and seminars and a shared partnering. Keynotes at this year's event will be given by Dr Tasuku Honjyo, President of the Foundation for Biomedical Research and Innovation, Mr Christophe Weber, President and CEO of Takeda Pharmaceutical and Mr Yuzo Toda, Chairman of the Forum for Innovative Regenerative Medicine, Director & Executive Vice President of Fujifilm Corp.

Welcome

GREETING As one of the major biotech markets, Japan has continued to be a key country for new business opportunities. BioJapan has been helping the growth



of the market with the combination of exhibitions, partnering and seminars. We are proud that over the few last years, BioJapan has become a mustattend-event in the Asia-Pacific region. Once again, our organising committee has joined forces to provide attendees with a high quality conference, an enriching exhibition and efficient partnering. Japan has made biotechnology, regenerative and personalised medicine an important pillar of its growth strategy, and regulatory changes have created an overall climate that is more favorable than ever before. In response to heightened expectations for the business opportunity in regenerative medicine, we will start "Regenerative Medicine JAPAN" along with BioJapan. We also hope that BioJapan attendees will enjoy Japan's hospitality. Bio Japan's social events will certainly contribute to making a participation in BioJapan 2016 a very special one. We look forward to seeing new and old friends in Yokohama.

> QUICK FACTS

Partnering participants' affiliation

33.9% Drug and drug discovery 12.7% Research institutes 10.8% CRO/CMO 13.2% Government office/ bio-related associations

Networking Events

October 12: Evening Reception October 13: Partnering Party http://www.ics-expo.jp/biojapan

Sakayu Shimizu

Chairman BioJapan Organizing Committee Open up a New Chapter of Bio-Business





BioJapan 2016





Regenerative Medicine

Pacifico Yokohama, JAPAN October 12th(Wed.)-14th(Fri.), 2016

President & CEO Takeda Pharmaceutical Co. Ltd.

PARTNERING

1,200 Participants 30 Countries

8,000 Meetings 2 Networking Parties Partnering registration will open in early-July

Registration Fee: JPY 60,000(approx. USD 545)


EXHIBITION

600 Exhibitors 25 Countries 15,000 Visitors

- · Global Pharma
- Biotech Ventures
- Research Institutes, University Labs
- Technology Licensing Organizations
- · CRO / CMO etc.
- Research equipment manufacturer

SEMINARS

From Market Overview to R&D Trend, 200 Organizer's Seminar and Exhibitors' Presentations





BIO-EUROPE®

NOVEMBER 7-9, 2016 COLOGNE, GERMANY

7-9 November, 2016 KoelnMesse, Congress Center North, Cologne, Germany

BIO-Europe 2016

PARTNERING The 22nd edition of BIO-Europe® international partnering conference is taking place in Cologne, Germany, from 7–9 November, 2016, bringing together top decision makers from global life science companies in search of in-licensing and investment opportunities for deals that propel drug development.

Cologne, Germany will host what the international life science industry considers to be its most productive annual partnering event, BIO-Europe®, taking place 7-9 November, 2016 at the KoelnMesse - Congress Center North. The main draw for executive-level decision makers from pharma, biotech and finance is what is known in the industry as "partnering." These one-to-one, private business devel-

opment and discovery meetings are the backbone of the event, and have led to some of the biggest M&A and collaborative deals over the past two decades.

Now in its 22nd edition, BIO-Europe is also highly regarded for the variety and high caliber of presenting companies, ranging from academic innovators and next generation companies to mid-size pharma and biotech, which

bring their innovative technologies, therapies and solutions to the event with the goal of securing development and commercialisation partners. If the partnering can be considered the engine, the presenting companies are the fuel that drives the event. BIO-Europe also features a diverse list of industry leaders speaking on panels and workshops.

Leading pharmaceutical companies, including all of the big names in pharma, sponsor the event, sending teams of scouts to engage in new and innovative products and ideas. Informal networking events in stunning local venues lend further dealmaking opportunities.

The 2015 event boasted an all-time record of 3,520 attendees, 19,153 scheduled one-to-one meetings with 4,358 licensing opportunities posted from among 1,886 companies that attended from 55 countries.

Good to see you!

GREETING There is tangible excitement around the arrival of BIO-Europe every year. This event is a key strategy for glo-



bal biotech, pharma and investors who attend in search of new collaboration partners and deal opportunities. Cologne is an ideal central European biotech hub that is expected to draw a high caliber of companies, not only from Germany but from across the globe, to fuel the insatiable drug development industry. With over 3,500 attendees last year, this event which pioneered partnering 22 years ago continues to stoke the engine that drives the industry's growing demand for transformational breakthroughs. See you in Cologne this November!

Anna Chrisman

Group Managing Director EBD Group

> QUICK FACTS

KEY DATES

05/08 – Presentation application deadline

31/08 – Early registration deadline

26/09 - PartneringOne opens

31/10 - First round of scheduling

04/11 - Online registration ends

07/11 – Onsite registrations begins

Phone +49 89 23 88 756 0 www.ebdgroup.com/bioeurope

Access a world of opportunities through life science partnering at BIO-Europe.

22ND ANNUAL INTERNATIONAL PARTNERING CONFERENCE

BIO-EUROPE®

COLOGNE, GERMANY // NOVEMBER 7-9, 2016

As Europe's largest life science partnering conference, BIO-Europe is singularly regarded as the annual "must attend" event for leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies.

WHAT YOU CAN EXPECT:

- 19,500+ one-to-one partnering meetings
- 4,300+ licensing opportunities
- 3,500+ attendees (75% top/senior management)
- 1,800+ companies representing 50+ countries

REGISTER NOW and save EUR 100

when you register by June 30 with code BEU16-EBN.

Find out more: ebdgroup.knect365.com/bioeurope

Produced by







8-9 November, 2016 Swissôtel Congress Centrum Düsseldorf/Neuss, Germany

Lab challenges

PHARMALAB PharmaLab has become the autumn convention for pharmaceutical QC professionals in analytics, bioanalytics and microbiology. And this year for the fourth time in a row, the Congress, together with a parallel exhibition, will pick up the latest developments.

The continued development of methods and laboratory systems in analytics/bioanalytics as well as in microbiology entailed the revision of the respective guidelines and monographs. And both also require QC laboratories to permanently progress. Some examples in analytics illustrate these changes:

New EU GMP requirements of Chapters 5 and 6 for the analytical lab:
 (1) Statistical Sampling Plans – now required according to new EU GMP

- Chapter 5? (2) Handling of OOT results as new requirement in EU GMP Chapter 6 how to realise in practice?
- > Future USP expectation: lifecycle management for analytical methods (including impact on changes/variations)
- ObD for analytical methods challenges and benefits

Moreover, in microbiology the subject masking in endotoxin testing continues to move minds. The European authorities' increased efforts to replace animal experiments like the rabbit pyrogen test with alternative methods, promote the establishment of laboratory systems. This particularly concerns the Monocyte Activation Test (MAT) which is an acknowledged pharmacopoeial method (see Ph. Eur. Chapter 2.6.30) in Europe, but is not a monograph outside of Europe. It also affects the now available recombinant factor C-based alternative Bacteria Endotoxin Tests (BETs).

Computer systems in laboratories are another area challenging personnel with permanent innovations. Data integrity, LIMS systems and their implementation as well as linking Electronic Laboratory Notebooks (ELNs) to existing systems are subjects which are increasingly gaining attention from inspectors.


With six international and four German speaking conferences, PharmaLab 2016 once more provides an excellent forum to become familiar with the current status of regulations, science and technology.

Professional forum

GREETING At PharmaLab 2015, we received plenty of acknowledgement from many of the around 300 delegates. So we look forward to welcoming you to the fourth edition of PharmaLab – on 8/9 No-



vember in Düsseldorf/ Neuss. About 60 experts from authorities, industry and contract labs as well as from research will bring you up-todate in terms of current regulatory developments, new methods and practical experience in the lab. Thus, you may want to think about joining our information ex-



Axel H. Schroeder (left) & Dr. Günter Brendelberger Concept Heidelberg, Operations Directors

> QUICK FACTS

CONTACT & REGISTRATION www.pharmalab-congress.com

HIGHLIGHTS

- Key Speakers from the US, Austria, UK and Germany
- > 10 conferences with over 50 lectures in English or German
- Current "hot topics" like low endotoxin recovery and data integrity
- Networking options & social event



No matter whether bioassays, chemical analytics or microbiological testing, PharmaLab provides the ideal forum to discuss current trends, developments and applications in the pharmaceutical lab. And for you as a solutions provider the PharmaLab exhibition is thus the right platform to present your latest technologies and services for the modern lab.

Create your own programme out of the following conferences:

Bioanalytics

Biosimilars Bioassays und Proteinanalytik*

Analytics

Laboratory Informatics
QC Compliance Trends
Laboroptimierung*
Leachables & Extractables*
Analytik von Wirk- und Hilfsstoffen*

Microbiology

Endotoxin and Pyrogen Testing Rapid Microbiological Methods Microbial Safety of Raw Materials and Excipients



Media Partner:







9–10 November, 2016 Hotel Pullman Brussels Midi, Brussels, Belgium

360° of biosimilars

4TH EUROPEAN BIOSIMILARS CONFERENCE Biosimilar medicines' developments are maintaining their momentum. As the 4th conference of its kind, the 2016 programme gives a complete 360-degree overview of biosimilar medicines

The 2016 Biosimilars Conference programme delves into strategic discussions regarding market and regulatory developments, enlightened by the perspective of healthcare professionals' and patients' experiences. It will look at the impact of biosimilar medicines on the competitive landscape of biological products in light of ten years of market existence and also look at national policy developments.

> QUICK FACTS

Highlights

A 360 degree overview of the field of biosimilars

Pharmacovigilance, regulation The last ten years: what we have learned

Contact

EMEA@DIAglobal.org Phone: +41 61 225 51 51 www.DIAglobal.org

What you will learn:

- Deal with regulatory requirements, scientific and operational challenges
- > Exchange experiences and discuss hot topics with experts
- Discuss the necessary conditions for optimal use

Featured topics:

- Current regulatory status of biosimilar medicines in the EU and globally
- Learnings from PhV practices for biologics and biosimilars
- Biological medicines in practice experiences and views of patients, pharmacists, nurses, physicians and procurers
- Key learnings from multi-stakeholder dialogue platforms on patients and healthcare professionals' information needs
- > The balance of risk and benefits
- > Clinical experience and real world evidence for biosimilar medicines

Participants will leave the conference with a wealth of new information and an expanded network of contacts.

In the real world

Welcome This years'
DIA European Biosimilars Conference
will have a strong focus on real-world use
of biosimilars. DIA and
the conference organ-



izing committee have aimed at bridging the gap between the regulatory landscape and end users of biosimilars: patients and prescribers. The attempt has been to incorporate the most interesting and contested topic to generate knowledge and especially to stimulate the discussion, exchange of ideas and point out the directions for the future. The target audience is diverse which we hope will give the best possible reflection of the current status of biosimilars in EU and around the globe. The sessions will include discussion of switching, evolving positions of healthcare professionals and patients and reflections on the challenges within the regulatory landscape, especially with regard to pharmacovigilance and future guidelines. The conference is a must-attend for any organization working with biosimilars or looking into expanding into the field. I am looking forward to welcome you to the conference.

Steffen Thirstrup


Conference Chair; Director and Advisory Board Member, NDA Advisory Services, UK; former CHMP-member and Head of Licensing, Danish Health and Medicines Authority

Advance your Knowledge in the Field of Biosimilars

Biosimilars Conference 2016

A European View on Biosimilar medicines with a Global Outlook

9-10 November 2016 Pullman Hotel Midi, Brussels, Belgium



- Market and regulatory developments in the EU and globally, enlightened by the perspective of healthcare professionals' and patients' experiences
- National policy developments (e.g. pricing, reimbursement, incentives, government investments)

Training Courses on

Biosimilar Medicines as a Business Opportunity - The Past and the Future

7-8 November 2016 Hotel Pullman Midi, Brussels, Belgium

This course focuses on real life examples and will provide professionals in development and planning roles with an understanding of the commercial landscape for biosimilar medicines, the obstacles being navigated, and present the learnings so far.

Learn more or register at www.diaglobal.org/
EuroBiosimilars

The course will focus on key topics such as:

- Market outlook for biosimilar medicines
- Regulatory and market access strategies
- Learnings from the launches until now







30 November - 1 December, 2016 Lille Grand Palais, Lille, France

Sourcing innovations

5TH BIOFIT With 1,300 attendees, BioFIT emerges as the leading partnering event in Europe for academia-industry collaborations, technology transfer and for sourcing early stage innovations in the field of life sciences.

With the highest attending rate of academics, TTOs and research institutes, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for sourcing early-stage innovations stemming from public research institutions, academic spinoffs and emerging biotech companies. Together with big pharma, biotech and diagnostics companies, BioFIT operates as a platform to build partner-

ships for all public and private actors. BioFIT is also the marketplace for seed investment with cutting-edge technologies.

Through the business convention, all attendees can schedule up to 30 one-to-one meetings over the two days. At the platform opening, one month before the event, they can identify potential partners among the registrants, but also licensing opportunities. Afterwards, each participant can manage his/her own schedule to save time and attend conferences or presentation sessions.

The panel discussions of BioFIT 2016 will feature around 60 high-level speakers around hot topics on the best practices in collaborative research, key issues in licensing and technology transfer and early stage financing.

Finally, in order to promote public research, the presentation sessions give young academic spin-offs entrepreneurs, researchers and tech transfer professionals the opportunity to present their projects and find industrial partners or investors who share their vision.

High points

Discover the 2016 conference programme of the 5th edition of BioFIT. The topic of the Plenary Session: Is Europe competitive enough in Life Sciences innovation?

Best practices in collaborative research

- How can industry and investor incubator models accelerate research translation?
- How can deal-making processes be accelerated by standard elements?

Key issues in licensing and tech transfer

- What is the best profile for an academic spin-off CEO?
- Are universities a short-term or long term partner for spin-offs?
- > To spin or not to spin?

Early stage innovation: identify the right funding sources

- Committed to the VC business: why and how universities take part in new venture funds?
- Lessons learned: dos & don'ts from seasoned entrepreneurs
- Does the European seed market exist?
- How to spark VCs interest in your company for Series A financing?
- How can former successful entrepreneurs become involved and support today's life sciences startups?

> QUICK FACTS

2015 figures

- > 1,150 delegates
- > 800 companies
- > 31 countries
- > 2,500 one-to meetings
- > 800 licensing opportunities

CONTACT

msatola@eurasante.com +33 (0)3 59 39 01 82 www.biofit-event.com





30th November and 1st December 2016

A 360° approach to build Life Sciences partnerships

WWW.BIOFIT-EVENT.COM - @BIOFIT_EVENT

SPECIAL OFFER

As a reader of **European Biotechnology Magazine** benefit from a 25% discount on BioFIT full pass

Your coupon code: "BF16-EuBioN" *

* Offers cannot be combined and apply to the full rate Organised by



In collaboration with





